Comparison of the relative efficacy of β-lactam/β-lactamase inhibitors and carbapenems in the treatment of complicated urinary tract infections caused by ceftriaxone-non-susceptible Enterobacterales: a multicentre retrospective observational cohort study

• Published in: Journal of antimicrobial chemotherapy 2023-03, Vol.78 (3), p.710-718
• Main Authors: Chen, Liang, Hua, Jie, Hong, Shu-Jie, Yuan, Chen-Yang, Jing, Ruo-Chen, Luo, Xuan-Yu, Xue, Hao-Wen, Yue, Yue, He, Xiao-Pu
• Format: Article
• Language: English
• Subjects: Anti-Bacterial Agents - therapeutic use; beta-Lactamase Inhibitors - therapeutic use; beta-Lactamases; beta-Lactams - therapeutic use; Carbapenems - therapeutic use; Ceftriaxone - therapeutic use; Enterobacteriaceae; Enterobacteriaceae Infections - drug therapy; Gammaproteobacteria; Humans; Lactams; Retrospective Studies; Urinary Tract Infections - drug therapy
• ISSN: 0305-7453; 1460-2091
• DOI: 10.1093/jac/dkac448

Abstract Background Treating complicated urinary tract infections (cUTIs) caused by ESBL-producing Enterobacterales represents a significant clinical challenge. The present study was thus developed to explore the relative efficacy of β-lactam/β-lactamase inhibitors (BLBLIs) and carbapenems for the treatment of hospitalized patients suffering from cUTIs caused by BLBLI-susceptible ceftriaxone-non-susceptible Enterobacterales. Methods Data from 557 patients from four Chinese teaching hospitals diagnosed with cUTIs caused by ceftriaxone-non-susceptible Enterobacterales from January 2017 to May 2022 were retrospectively assessed. Result The 30 day rate of treatment failure, defined by unresolved symptoms or mortality, was 10.4% (58/557). Independent predictors of 30 day treatment failure included immunocompromised status, bacteraemia, septic shock, lack of infection source control and appropriate empirical treatment. When data were controlled for potential confounding variables, BLBLI treatment exhibited a comparable risk of 14 day (OR 1.61, 95% CI 0.86–3.00, P = 0.133) and 30 day treatment failure (OR 1.45, 95% CI 0.66–3.15, P = 0.354) relative to carbapenem treatment for the overall cohort of patients. In contrast, BLBLI treatment in immunocompromised patients was associated with an elevated risk of both 14 day (OR 3.18, 95% CI 1.43–7.10, P = 0.005) and 30 day treatment failure (OR 3.06, 95% CI 1.07–8.80, P = 0.038) relative to carbapenem treatment. Conclusions These results suggested that carbapenem treatment may be superior to BLBLI treatment for immunocompromised patients suffering from cUTIs caused by ceftriaxone-non-susceptible Enterobacterales species. However, these results will need to be validated in appropriately constructed randomized controlled trials to ensure appropriate patient treatment.